Q4 2024 Earnings Call Transcript February 18, 2025 Halozyme Therapeutics, Inc. beats earnings expectations. Reported EPS is ...

Halozyme reports better-than-expected fourth-quarter 2024 results. The company maintains revenue guidance for 2025.

Helen Torley; President, Chief Executive Officer, Director; Halozyme Therapeutics Inc Nicole Labrosse; Chief Financial Officer, Senior Vice President; Halozyme Therapeutics Inc Good afternoon. My name ...

Reported encouraging early safety and efficacy data in ongoing dose escalation trial for ORIC-944 in combination with androgen receptor ...

Merck’s Keytruda may be the most talked about drug facing loss of exclusivity but it’s far from the only one, as several of ...

Opdualag – which combines the PD-1 inhibitor nivolumab in BMS' blockbuster cancer drug Opdivo with LAG-3 inhibitor relatlimab ...

Novo Nordisk has been looking to diversify its lineup in recent years, and is developing medicines in other fields. The ...

Find out if it's safe to drink alcohol during your Ozempic treatment, whether alcohol raises the risk of any sides effects, ...

Rupert’s shocking decision was the climax of a succession battle that had pitted James and Lachlan, born just 15 months apart ...

EQS-News: SCHOTT Pharma AG & Co. KGaA / Key word (s): Quarterly / Interim Statement/Quarter Results SCHOTT Pharma records good start into fiscal year and confirms full year outlook 13.02.2025 / ...

Three stocks that may be underrated options for dividend investors to consider today are PepsiCo ( PEP -0.82%), United Parcel ...

The subcutaneous version of $25 billion-a-year ... in which the formulation matched Opdivo on safety and efficacy measures as a second-line treatment for patients with kidney cancer.